1
|
Gionfriddo TB, Georoff T, Baker K, Ialeggio D, Hinshaw K, Toddes B, Trupkiewicz JG. INTESTINAL TYMPANY AND VOLVULUS IN CENTRAL AMERICAN RIVER TURTLES ( DERMATEMYS MAWII). J Zoo Wildl Med 2024; 55:224-234. [PMID: 38453507 DOI: 10.1638/2021-0109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/01/2023] [Indexed: 03/09/2024] Open
Abstract
Ten cases of small intestinal tympany with or without volvulus were documented in Central American river turtles (Dermatemys mawii). These turtles were under managed care at the Philadelphia Zoo in Philadelphia, PA, USA, with one case followed after transfer to a different institution. The primary clinical presentation was abnormal buoyancy in nearly all cases (9/10) and anorexia in two cases (2/10). Five of 10 turtles with suspected or radiographically confirmed small intestinal tympany recovered (5/10), whereas five cases (5/ 10) resulted in death or euthanasia. In all fatal cases (5/5), small intestinal volvulus was identified at gross necropsy, with concurrent colonic volvulus identified in 2/5 cases. Other notable necropsy findings were hepatic lipidosis (3/5) and thrombosis of intestinal or renal vasculature (2/5). In all fatal cases (5/5), there was short (1 to 2 days) clinical progression from abnormal buoyancy to death or euthanasia. In the majority of cases (6/10), an abrupt change in diet, notably the overfeeding of fresh fruit or excessive amounts of mulberry (Morus spp.) browse, or ingestion of indigestible foreign material, occurred prior to presentation. Temporary suboptimal environmental temperatures were suspected prior to the onset of clinical signs in 4/10 cases. Optimal husbandry conditions including nutrition and environmental temperature appear vital to preventing this condition. Recognition of early clinical signs of this condition, such as abnormal buoyancy and anorexia, and environmental correction or medical therapy, may prevent fatality and result in a better outcome in these cases.
Collapse
Affiliation(s)
| | - Tim Georoff
- The Philadelphia Zoo, Philadelphia, PA 19104-1196, USA
| | - Kendra Baker
- The Philadelphia Zoo, Philadelphia, PA 19104-1196, USA
- The National Aquarium, Baltimore, MD 21202, USA
| | | | - Keith Hinshaw
- The Philadelphia Zoo, Philadelphia, PA 19104-1196, USA
| | | | | |
Collapse
|
2
|
LePore L, Kronfli D, Baker K, Eggleston C, Bentzen SM, Mohindra P, Vyfhuis MAL. Identifying and Addressing Nutritional Inequities and Psychosocial Needs of Cancer Patients Residing in Zip-Code Designated Food Priority Areas (FPAs). Int J Radiat Oncol Biol Phys 2023; 117:e34-e35. [PMID: 37785187 DOI: 10.1016/j.ijrobp.2023.06.723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Nutrition is an essential aspect of cancer care at all time points leading to and after definitive therapy. Yet, cancer patients who reside in FPAs may experience limited access to healthy meals, possibly affecting cancer outcomes. There is no prospective data evaluating the consequence of residing in FPAs as it relates to perceived nutritional access, psychosocial needs, or nutritional status of cancer patients before, during, and after definitive treatment. Therefore, this study aims to characterize the nutritional needs of cancer patients undergoing curative radiation treatment (RT). We hypothesize that FPA residence will correlate with perceived lack of access to healthy food as well as other unmet psychosocial cancer needs at multiple time points during care. MATERIALS/METHODS Under IRB approval, a prospective, cross-sectional analysis was done using a questionnaire consolidated from previously validated surveys assessing the nutritional and psychosocial needs of patients with curable lung, head/neck, gynecological, or gastrointestinal cancers at different time points of cancer care (pre-treatment, 1 month, 6 months, and 1 year after completion of RT). Groups were compared using Χ2 and Mann-Whitney U tests as appropriate. Binary logistic regression was used to identify predictors of healthy food access. RESULTS From May 2019 to December 2022, 320 of 434 patients completed the survey, giving a compliance rate of 74%. Twenty-six percent of patients resided in zip-code designated FPAs. Patients who lived in FPAs were more likely to self-identify as black (60.5% vs 39.5%; p<0.001), single (p<0.001), have a lower median income (p<0.001), and were more likely to receive care at our inner-city photon therapy center (p<0.001) compared to non-FPA residents. Compared with non-FPA patients, the cohort who lived in FPAs had higher unmet nutritional needs (p = 0.003), which included a greater demand for healthier ways to eat (67.6%vs.54.4; p = 0.047) and a greater concern of having inadequate funds to buy healthy meals (44.4%vs.19.9%; p = 0.002). On MVA, marital status, median income, race, educational level and FPA residence were included, however only black race (OR:8.85; 95% CI:3.73-16.32; p<0.001) and education level (Elementary School: OR:8.32; 95% CI:1.19-58.33; p = 0.001, REF: Graduate/Professional) were predictors for nutritious meals uncertainty. CONCLUSION Inequities in nutritional needs were clearly identified in patients residing in FPAs when compared to non-FPA patients. Race and educational level are important factors in identifying patients in need of nutritional support. These demographics along with FPA-designated zip codes can be used to identify at-risk patients during clinic visits, where continuous nutritional and psychosocial support can be provided.
Collapse
Affiliation(s)
- L LePore
- University of Maryland School of Medicine, Baltimore, MD
| | - D Kronfli
- University of Maryland School of Medicine, Baltimore, MD
| | - K Baker
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - C Eggleston
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - S M Bentzen
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - P Mohindra
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD; Maryland Proton Treatment Center, Baltimore, MD
| | - M A L Vyfhuis
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD; Maryland Proton Treatment Center, Baltimore, MD
| |
Collapse
|
3
|
Allen AJ, Savla B, Datnow-Martinez C, Mendes W, Kamran SC, Ambs S, Eggleston C, Baker K, Molitoris JK, Ferris MJ, Patel AN, Rana ZH, Kunaprayoon D, Hong JJ, Davicioni E, Mishra MV, Bentzen SM, Jr WFR, Kwok Y, Vyfhuis MAL. A Precision Medicine Navigator Can Mitigate Inequities Associated with Utilization of Genomic Tests in Black Men with Prostate Cancer. Int J Radiat Oncol Biol Phys 2023; 117:S15-S16. [PMID: 37784380 DOI: 10.1016/j.ijrobp.2023.06.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Black men with prostate cancer in the United States experience disproportionately worse clinical outcomes compared to other racial groups. Identifying more reliable prognosticators to address these inequities has thus been the subject of considerable research scrutiny. However, prognostic genomic tools and genomic biorepositories suffer from an even greater lack of racial diversity. Strategies to mitigate these amplifying developments in inequities are desperately needed. We hypothesized that the presence of a precision medicine navigator (PMN) may mitigate inequities with standard of care (SOC) genomic test utilization among Black men with prostate cancer. MATERIALS/METHODS We retrospectively reviewed prostate cancer consults within one healthcare system from 11/2/2021 to 1/2/2022. We compared the frequency of patients who received SOC Decipher or Tempus genomic testing in the 7 months prior to the PMN start (pre-PMN) to the 7 months afterward (post-PMN). Chi square analysis was used to compare subgroups. Binary logistic regression was used to calculate the odds of receiving genomic testing. RESULTS The sample included 693 patients, 44.9% (311/693) pre-PMN and 55.1% (382/693) post-PMN, with a median age of 68 in both groups. Pre- and post-PMN racial distributions were similar with 60.1% and 60.2% White, 35.1% and 34% Black, 3.2% and 3.7% Asian/Pacific Islander, and 1.3% and 2.1% Latino, respectively. Pre- and post-PMN NCCN risk category distribution was 15.2% and 10.4% low risk, 46.8% and 49.9% intermediate risk, and 38.1% and 39.7% high risk, respectively. Pre- and post-PMN groups had 14.5% and 17% distant metastases, 77.2% and 76.9% localized disease, 10.3% and 10% prior prostatectomy, 47% and 51% income below sample median, 51% and 52% with Medicare/Medicaid, and 47% and 48% seen at community hospitals, respectively. There were no statistically significant differences for these variables pre- and post-PMN. However, from pre- to post-PMN, the proportion of Black patients receiving genomic testing increased from 19% to 58%. Black patients seen post-PMN were six times more likely to receive testing (p<0.001). Significant increases in SOC genomic testing post-PMN also occurred among lower median income patients, patients with Medicare/Medicaid, and community hospital patients. CONCLUSION The presence of a PMN may improve disparate rates of Black patients receiving SOC genomic tests for prostate cancer compared to other racial groups and may alleviate genomic testing inequities among other demographics.
Collapse
Affiliation(s)
- A J Allen
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - B Savla
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - C Datnow-Martinez
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - W Mendes
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - S C Kamran
- Massachusetts General Hospital, Boston, MA
| | - S Ambs
- Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD
| | - C Eggleston
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - K Baker
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - J K Molitoris
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - M J Ferris
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - A N Patel
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - Z H Rana
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - D Kunaprayoon
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - J J Hong
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | | | - M V Mishra
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - S M Bentzen
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD; Division of Biostatistics and Bioinformatics, University of Maryland Greenebaum Cancer Center, and Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD
| | - W F Regine Jr
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - Y Kwok
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - M A L Vyfhuis
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| |
Collapse
|
4
|
Milling TJ, Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, Verhamme P, Cohen AT, Beyer-Westendorf J, Michael Gibson C, Lopez-Sendon J, Crowther M, Shoamanesh A, Coppens M, Schmidt J, Albaladejo P, Connolly SJ, Bastani A, Clark C, Concha M, Cornell J, Dombrowski K, Fermann G, Fulmer J, Goldstein J, Kereiakes D, Milling T, Pallin D, Patel N, Refaai M, Rehman M, Schmaier A, Schwarz E, Shillinglaw W, Spohn M, Takata T, Venkat A, Welker J, Welsby I, Wilson J, Van Keer L, Verschuren F, Blostein M, Eikelboom J, Althaus K, Berrouschot J, Braun G, Doeppner T, Dziewas R, Genth-Zotz S, Greinacher P, Hamann F, Hanses F, Heide W, Kallmuenzer B, Kermer P, Poli S, Royl G, Schellong S, Schnupp S, Schwarze J, Spies C, Thomalla G, von Mering M, Weissenborn K, Wollenweber F, Gumbinger C, Jaschinski U, Maschke M, Mochmann HC, Pfeilschifter W, Pohlmann C, Zahn R, Bouzat P, Schmidt J, Vallejo C, Floccard B, Coppens M, van Wissen S, Arellano-Rodrigo E, Valles E, Alikhan R, Breen K, Hall R, Crowther M, Albaladejo P, Cohen A, Demchuk A, Schmidt J, Wyse D, Garcia D, Prins M, Nakamya J, Büller H, Mahaffey KW, Alexander JH, Cairns J, Hart R, Joyner C, Raskob G, Schulman S, Veltkamp R, Meeks B, Zotova E, Ahmad S, Pinto T, Baker K, Dykstra A, Holadyk-Gris I, Malvaso A, Demchuk A. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation 2023; 147:1026-1038. [PMID: 36802876 DOI: 10.1161/circulationaha.121.057844] [Citation(s) in RCA: 20] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
BACKGROUND Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b/4, single-group cohort study that evaluated andexanet alfa in patients with acute major bleeding. The results of the final analyses are presented. METHODS Patients with acute major bleeding within 18 hours of FXa inhibitor administration were enrolled. Co-primary end points were anti-FXa activity change from baseline during andexanet alfa treatment and excellent or good hemostatic efficacy, defined by a scale used in previous reversal studies, at 12 hours. The efficacy population included patients with baseline anti-FXa activity levels above predefined thresholds (≥75 ng/mL for apixaban and rivaroxaban, ≥40 ng/mL for edoxaban, and ≥0.25 IU/mL for enoxaparin; reported in the same units used for calibrators) who were adjudicated as meeting major bleeding criteria (modified International Society of Thrombosis and Haemostasis definition). The safety population included all patients. Major bleeding criteria, hemostatic efficacy, thrombotic events (stratified by occurring before or after restart of either prophylactic [ie, a lower dose, for prevention rather than treatment] or full-dose oral anticoagulation), and deaths were assessed by an independent adjudication committee. Median endogenous thrombin potential at baseline and across the follow-up period was a secondary outcome. RESULTS There were 479 patients enrolled (mean age, 78 years; 54% male, 86% White; 81% anticoagulated for atrial fibrillation at a median time of 11.4 hours since last dose, with 245 (51%) on apixaban, 176 (37%) on rivaroxaban, 36 (8%) on edoxaban, and 22 (5%) on enoxaparin. Bleeding was predominantly intracranial (n=331 [69%]) or gastrointestinal (n=109 [23%]). In evaluable apixaban patients (n=172), median anti-FXa activity decreased from 146.9 ng/mL to 10.0 ng/mL (reduction, 93% [95% CI, 94-93]); in rivaroxaban patients (n=132), it decreased from 214.6 ng/mL to 10.8 ng/mL (94% [95% CI, 95-93]); in edoxaban patients (n=28), it decreased from 121.1 ng/mL to 24.4 ng/mL (71% [95% CI, 82-65); and in enoxaparin patients (n=17), it decreased from 0.48 IU/mL to 0.11 IU/mL (75% [95% CI, 79-67]). Excellent or good hemostasis occurred in 274 of 342 evaluable patients (80% [95% CI, 75-84]). In the safety population, thrombotic events occurred in 50 patients (10%); in 16 patients, this occurred during treatment with prophylactic anticoagulation that began after the bleeding event. No thrombotic episodes occurred after oral anticoagulation restart. Specific to certain populations, reduction of anti-FXa activity from baseline to nadir significantly predicted hemostatic efficacy in patients with intracranial hemorrhage (area under the receiver operating characteristic curve, 0.62 [95% CI, 0.54-0.70]) and correlated with lower mortality in patients <75 years of age (adjusted P=0.022; unadjusted P=0.003). Median endogenous thrombin potential was within the normal range by the end of andexanet alfa bolus through 24 hours for all FXa inhibitors. CONCLUSIONS In patients with major bleeding associated with the use of FXa inhibitors, treatment with andexanet alfa reduced anti-FXa activity and was associated with good or excellent hemostatic efficacy in 80% of patients. REGISTRATION URL: https://www. CLINICALTRIALS gov; Unique identifier: NCT02329327.
Collapse
Affiliation(s)
- Truman J Milling
- Seton Dell Medical School Stroke Institute, Dell Medical School, University of Texas at Austin (T.J.M.)
| | - Saskia Middeldorp
- Department of Internal Medicine and Radboud Institute of Health Sciences, Nijmegenthe Netherlands (S.M.)
| | - Lizhen Xu
- Population Health Research Institute, McMaster University, HamiltonOntario Canada. (L.X., A.S., S.J.C.)
| | - Bruce Koch
- Alexion, AstraZeneca Rare Disease, BostonMA (B.K.)
| | - Andrew Demchuk
- Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, AlbertaCanada (A.D.)
| | - John W Eikelboom
- Department of Medicine, McMaster University, HamiltonOntario Canada. (J.W.E., M. Crowther)
| | - Peter Verhamme
- Center for Molecular and Vascular Biology, University of Leuven, Belgium (P.V.)
| | | | - Jan Beyer-Westendorf
- Department of Medicine I, Division of Hematology and Hemostasis, University Hospital Dresden, Germany (J.B-W.)
| | | | - Jose Lopez-Sendon
- Instituto de Investigación Hospital Universitario, La PazMadridSpain (J. L-S.)
| | - Mark Crowther
- Department of Medicine, McMaster University, HamiltonOntario Canada. (J.W.E., M. Crowther)
| | - Ashkan Shoamanesh
- Population Health Research Institute, McMaster University, HamiltonOntario Canada. (L.X., A.S., S.J.C.)
| | - Michiel Coppens
- Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands (M. Coppens)
| | - Jeannot Schmidt
- Centre Hospitalier Universitaire de Clermont-Ferrand, France (J.S.)
| | | | - Stuart J Connolly
- Population Health Research Institute, McMaster University, HamiltonOntario Canada. (L.X., A.S., S.J.C.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Keane JM, Walsh CJ, Cronin P, Baker K, Melgar S, Cotter PD, Joyce SA, Gahan CGM, Houston A, Hyland NP. Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints. Br J Cancer 2023; 128:528-536. [PMID: 36418894 PMCID: PMC9938136 DOI: 10.1038/s41416-022-02062-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 11/03/2022] [Accepted: 11/08/2022] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Distinct sets of microbes contribute to colorectal cancer (CRC) initiation and progression. Some occur due to the evolving intestinal environment but may not contribute to disease. In contrast, others may play an important role at particular times during the tumorigenic process. Here, we describe changes in the microbiota and host over the course of azoxymethane (AOM)-induced tumorigenesis. METHODS Mice were administered AOM or PBS and were euthanised 8, 12, 24 and 48 weeks later. Samples were analysed using 16S rRNA gene sequencing, UPLC-MS and qRT-PCR. RESULTS The microbiota and bile acid profile showed distinct changes at each timepoint. The inflammatory response became apparent at weeks 12 and 24. Moreover, significant correlations between individual taxa, cytokines and bile acids were detected. One co-abundance group (CAG) differed significantly between PBS- and AOM-treated mice at week 24. Correlation analysis also revealed significant associations between CAGs, bile acids and the bile acid transporter, ASBT. Aberrant crypt foci and adenomas were first detectable at weeks 24 and 48, respectively. CONCLUSION The observed changes precede host hyperplastic transformation and may represent early therapeutic targets for the prevention or management of CRC at specific timepoints in the tumorigenic process.
Collapse
Affiliation(s)
- J M Keane
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- School of Microbiology, University College Cork, Cork, Ireland
- Department of Medicine, University College Cork, Cork, Ireland
- School of Biochemistry and Cell Biology, University College Cork, Cork, Ireland
- Department of Physiology, University College Cork, Cork, Ireland
| | - C J Walsh
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- Teagasc Food Research Centre, Moorepark, Fermoy, Cork, Ireland
| | - P Cronin
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- School of Biochemistry and Cell Biology, University College Cork, Cork, Ireland
| | - K Baker
- Department of Medicine, University College Cork, Cork, Ireland
- Department of Pathology, University College Cork, Cork, Ireland
| | - S Melgar
- APC Microbiome Ireland, University College Cork, Cork, Ireland
| | - P D Cotter
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- Teagasc Food Research Centre, Moorepark, Fermoy, Cork, Ireland
| | - S A Joyce
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- School of Biochemistry and Cell Biology, University College Cork, Cork, Ireland
| | - C G M Gahan
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- School of Microbiology, University College Cork, Cork, Ireland
- School of Pharmacy, University College Cork, Cork, Ireland
| | - A Houston
- APC Microbiome Ireland, University College Cork, Cork, Ireland.
- Department of Medicine, University College Cork, Cork, Ireland.
| | - N P Hyland
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- Department of Physiology, University College Cork, Cork, Ireland
| |
Collapse
|
6
|
Carvajal LA, Robinson B, Kosaka Y, Jacob T, Lee J, Hood T, Baker K, Kaempf A, Amara SNA, Pucilowska J, Lind E, Tognon C, Tyner J, Kumar P, Vu T, DiMartino J. P392: PHARMACOLOGICAL INHIBITION OF SYK CONFERS ANTI-PROLIFERATIVE AND NOVEL ANTI-TUMOR IMMUNE RESPONSES IN AML. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000844456.64162.e9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
7
|
Momin A, Hermann J, Baker K, Machado A. 420 Task Related Physiology of the Dentalothalamocortical Circuit in Naïve and Stroke Rats. Neurosurgery 2022. [DOI: 10.1227/neu.0000000000001880_420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
8
|
Knight H, Jia R, Ayling K, Bradbury K, Baker K, Chalder T, Morling JR, Durrant L, Avery T, Ball JK, Barker C, Bennett R, McKeever T, Vedhara K. Understanding and addressing vaccine hesitancy in the context of COVID-19: development of a digital intervention. Public Health 2021; 201:98-107. [PMID: 34801843 PMCID: PMC8520885 DOI: 10.1016/j.puhe.2021.10.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 09/29/2021] [Accepted: 10/10/2021] [Indexed: 11/06/2022]
Abstract
OBJECTIVES Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) was identified in late 2019, spreading to over 200 countries and resulting in almost two million deaths worldwide. The emergence of safe and effective vaccines provides a route out of the pandemic, with vaccination uptake of 75-90% needed to achieve population protection. Vaccine hesitancy is problematic for vaccine rollout; global reports suggest only 73% of the population may agree to being vaccinated. As a result, there is an urgent need to develop equitable and accessible interventions to address vaccine hesitancy at the population level. STUDY DESIGN & Method: We report the development of a scalable digital intervention seeking to address COVID-19 vaccine hesitancy and enhance uptake of COVID-19 vaccines in the United Kingdom. Guided by motivational interviewing (MI) principles, the intervention includes a series of therapeutic dialogues addressing 10 key concerns of vaccine-hesitant individuals. Development of the intervention occurred linearly across four stages. During stage 1, we identified common reasons for COVID-19 vaccine hesitancy through analysis of existing survey data, a rapid systematic literature review, and public engagement workshops. Stage 2 comprised qualitative interviews with medical, immunological, and public health experts. Rapid content and thematic analysis of the data provided evidence-based responses to common vaccine concerns. Stage 3 involved the development of therapeutic dialogues through workshops with psychological and digital behaviour change experts. Dialogues were developed to address concerns using MI principles, including embracing resistance and supporting self-efficacy. Finally, stage 4 involved digitisation of the dialogues and pilot testing with members of the public. DISCUSSION The digital intervention provides an evidence-based approach to addressing vaccine hesitancy through MI principles. The dialogues are user-selected, allowing exploration of relevant issues associated with hesitancy in a non-judgmental context. The text-based content and digital format allow for rapid modification to changing information and scalability for wider dissemination.
Collapse
Affiliation(s)
- H Knight
- University of Nottingham, School of Medicine, Nottingham, UK
| | - R Jia
- University of Nottingham, School of Medicine, Nottingham, UK
| | - K Ayling
- University of Nottingham, School of Medicine, Nottingham, UK
| | - K Bradbury
- National Institute for Health Research (NIHR) ARC Wessex, UK; University of Southampton, Department of Psychology, Southampton, UK
| | - K Baker
- National Institute for Health Research (NIHR) ARC Wessex, UK
| | - T Chalder
- Kings College London, Department of Psychological Medicine, London, UK
| | - J R Morling
- University of Nottingham, School of Medicine, Nottingham, UK; National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK
| | - L Durrant
- University of Nottingham, School of Medicine, Nottingham, UK
| | - T Avery
- University of Nottingham, School of Medicine, Nottingham, UK
| | - J K Ball
- University of Nottingham, School of Life Sciences, Nottingham, UK
| | - C Barker
- National Institute for Health Research (NIHR) ARC Wessex, UK
| | | | - T McKeever
- University of Nottingham, School of Medicine, Nottingham, UK
| | - K Vedhara
- University of Nottingham, School of Medicine, Nottingham, UK.
| |
Collapse
|
9
|
Bakewell Z, Wilkinson A, Todd F, Okocha M, Baker K, McCarthy K. 837 High Prevalence of Anaemia and Mortality in Older Patients Undergoing Emergency Laparotomy. Br J Surg 2021. [DOI: 10.1093/bjs/znab259.522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Aim
Anaemia affects 1in10 elderly (>65) patients with a myriad of causes. Elderly patients undergoing emergency laparotomy often present with anaemia. Little is known however about the prevalence of anaemia in older people who require emergency laparotomy and the influence it may have on their outcomes.
Method
Elderly patients (>65-years old) undergoing an emergency laparotomy between May2016-November2018 in a tertiary trauma centre were prospectively identified. Data included patient demographics, haemoglobin, MCV and ferritin, blood transfusions and iron products administered, readmissions and mortality.
Results
231 patients underwent emergency laparotomy. Prevalence of pre-operative anaemia in this group was 43%. 5% were very-anaemic and 38% mildly-anaemic. Ferritin was checked within 89 patients; insufficient levels were present in 20%. 31% of all patients were given blood in the peri-operative period. 100% of patients discharged, were anaemic. For pre-operative anaemic vs non-anaemic patients, ASA grade was higher (4 vs 3), readmission rate was 19% vs 18%, 30-day mortality was 18% vs 14% and 1-year mortality rate high(34% vs 22%, p < 0.05). Very-anaemic patients (92%) received peri-operative blood compared to (41%) of mildly-anaemic patients. 30-day mortality was 0 vs 21% in very-anaemic vs mildly-anaemic patients. Mortality was 45.8% in patients who received transfusions compared to those who did not 19.9% (P < 0.0001).
Conclusions
The prevalence of anaemia in older patients undergoing emergency laparotomy is high and related to significantly increased mortality(12 months after surgery). We have identified a high-risk group of older patients with mild anaemia on presentation who may be at increased risk of mortality 3months after surgery.
Collapse
Affiliation(s)
- Z Bakewell
- General Surgery, Southmead Hospital, Bristol, United Kingdom
| | - A Wilkinson
- General Surgery, Southmead Hospital, Bristol, United Kingdom
| | - F Todd
- General Surgery, Southmead Hospital, Bristol, United Kingdom
| | - M Okocha
- General Surgery, Southmead Hospital, Bristol, United Kingdom
| | - K Baker
- General Surgery, Southmead Hospital, Bristol, United Kingdom
| | - K McCarthy
- General Surgery, Southmead Hospital, Bristol, United Kingdom
| |
Collapse
|
10
|
Huffman B, Budde G, Chao J, Dayyani F, Hanna D, Botta G, Krinshpun S, Sharma S, Aushev V, Farmer T, Pela H, Tavallai M, Goodman M, Baker K, Drummond B, Aleshin A, Kasi P, Klempner S. 1415P Performance of a tumor-informed circulating tumor DNA assay from over 250 patients with over 600 plasma time points in esophageal and gastric cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1524] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
11
|
Zylstra AB, Kritcher AL, Hurricane OA, Callahan DA, Baker K, Braun T, Casey DT, Clark D, Clark K, Döppner T, Divol L, Hinkel DE, Hohenberger M, Kong C, Landen OL, Nikroo A, Pak A, Patel P, Ralph JE, Rice N, Tommasini R, Schoff M, Stadermann M, Strozzi D, Weber C, Young C, Wild C, Town RPJ, Edwards MJ. Record Energetics for an Inertial Fusion Implosion at NIF. Phys Rev Lett 2021; 126:025001. [PMID: 33512226 DOI: 10.1103/physrevlett.126.025001] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Revised: 10/27/2020] [Accepted: 12/10/2020] [Indexed: 06/12/2023]
Abstract
Inertial confinement fusion seeks to create burning plasma conditions in a spherical capsule implosion, which requires efficiently absorbing the driver energy in the capsule, transferring that energy into kinetic energy of the imploding DT fuel and then into internal energy of the fuel at stagnation. We report new implosions conducted on the National Ignition Facility (NIF) with several improvements on recent work [Phys. Rev. Lett. 120, 245003 (2018)PRLTAO0031-900710.1103/PhysRevLett.120.245003; Phys. Rev. E 102, 023210 (2020)PRESCM2470-004510.1103/PhysRevE.102.023210]: larger capsules, thicker fuel layers to mitigate fuel-ablator mix, and new symmetry control via cross-beam energy transfer; at modest velocities, these experiments achieve record values for the implosion energetics figures of merit as well as fusion yield for a NIF experiment.
Collapse
Affiliation(s)
- A B Zylstra
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A L Kritcher
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - O A Hurricane
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D A Callahan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Baker
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - T Braun
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D T Casey
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D Clark
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Clark
- General Atomics, San Diego, California 92121, USA
| | - T Döppner
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - L Divol
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D E Hinkel
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Hohenberger
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Kong
- General Atomics, San Diego, California 92121, USA
| | - O L Landen
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Nikroo
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Pak
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - P Patel
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J E Ralph
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - N Rice
- General Atomics, San Diego, California 92121, USA
| | - R Tommasini
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Schoff
- General Atomics, San Diego, California 92121, USA
| | - M Stadermann
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D Strozzi
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Weber
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Young
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Wild
- Diamond Materials Gmbh, 79108 Freiburg, Germany
| | - R P J Town
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M J Edwards
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| |
Collapse
|
12
|
Casey DT, MacGowan BJ, Sater JD, Zylstra AB, Landen OL, Milovich J, Hurricane OA, Kritcher AL, Hohenberger M, Baker K, Le Pape S, Döppner T, Weber C, Huang H, Kong C, Biener J, Young CV, Haan S, Nora RC, Ross S, Robey H, Stadermann M, Nikroo A, Callahan DA, Bionta RM, Hahn KD, Moore AS, Schlossberg D, Bruhn M, Sequoia K, Rice N, Farrell M, Wild C. Evidence of Three-Dimensional Asymmetries Seeded by High-Density Carbon-Ablator Nonuniformity in Experiments at the National Ignition Facility. Phys Rev Lett 2021; 126:025002. [PMID: 33512229 DOI: 10.1103/physrevlett.126.025002] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Revised: 10/22/2020] [Accepted: 11/30/2020] [Indexed: 06/12/2023]
Abstract
Inertial confinement fusion implosions must achieve high in-flight shell velocity, sufficient energy coupling between the hot spot and imploding shell, and high areal density (ρR=∫ρdr) at stagnation. Asymmetries in ρR degrade the coupling of shell kinetic energy to the hot spot and reduce the confinement of that energy. We present the first evidence that nonuniformity in the ablator shell thickness (∼0.5% of the total thickness) in high-density carbon experiments is a significant cause for observed 3D ρR asymmetries at the National Ignition Facility. These shell-thickness nonuniformities have significantly impacted some recent experiments leading to ρR asymmetries on the order of ∼25% of the average ρR and hot spot velocities of ∼100 km/s. This work reveals the origin of a significant implosion performance degradation in ignition experiments and places stringent new requirements on capsule thickness metrology and symmetry.
Collapse
Affiliation(s)
- D T Casey
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B J MacGowan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J D Sater
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A B Zylstra
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - O L Landen
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Milovich
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - O A Hurricane
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A L Kritcher
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Hohenberger
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Baker
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S Le Pape
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - T Döppner
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Weber
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - H Huang
- General Atomics, San Diego, California 92186, USA
| | - C Kong
- General Atomics, San Diego, California 92186, USA
| | - J Biener
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C V Young
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S Haan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - R C Nora
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S Ross
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - H Robey
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Stadermann
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Nikroo
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D A Callahan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - R M Bionta
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K D Hahn
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A S Moore
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D Schlossberg
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Bruhn
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Sequoia
- General Atomics, San Diego, California 92186, USA
| | - N Rice
- General Atomics, San Diego, California 92186, USA
| | - M Farrell
- General Atomics, San Diego, California 92186, USA
| | - C Wild
- Diamond Materials, 79108 Freiburg, Germany
| |
Collapse
|
13
|
Haskins C, Kronfli D, Lievers A, Waldo L, Baker K, Bentzen S, Mohindra P, Vyfhuis M. Characterizing Definitively Treated Cancer Patients Living Within Food Priority Areas (FPAs) to Find Predictors of Perceived Access to Healthy Meals. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
Moore AS, Meezan NB, Milovich J, Johnson S, Heredia R, Baumann TF, Biener M, Bhandarkar SD, Chen H, Divol L, Izumi N, Nikroo A, Baker K, Jones O, Landen OL, Hsing WW, Moody JD, Thomas CA, Lahmann B, Williams J, Alfonso N, Schoff ME. Foam-lined hohlraum, inertial confinement fusion experiments on the National Ignition Facility. Phys Rev E 2020; 102:051201. [PMID: 33327093 DOI: 10.1103/physreve.102.051201] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Accepted: 10/30/2020] [Indexed: 11/07/2022]
Abstract
Experiments on the National Ignition Facility (NIF) to study hohlraums lined with a 20-mg/cc 400-μm-thick Ta_{2}O_{5} aerogel at full scale (hohlraum diameter = 6.72 mm) are reported. Driven with a 1.6-MJ, 450-TW laser pulse, the performance of the foam liner is diagnosed using implosion hot-spot symmetry measurements of the high-density carbon (HDC) capsule and measurement of inner beam propagation through a thin-wall 8-μm Au window in the hohlraum. Results show an improved capsule performance due to laser energy deposition further inside the hohlraum, leading to a modest increase in x-ray drive and reduced preheat due to changes in the x-ray spectrum when the foam liner is included. In addition, the outer cone bubble uniformity is improved, but the predicted improvement in inner beam propagation to improve symmetry control is not realized for this foam thickness and density.
Collapse
Affiliation(s)
- A S Moore
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - N B Meezan
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - J Milovich
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - S Johnson
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - R Heredia
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - T F Baumann
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - M Biener
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - S D Bhandarkar
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - H Chen
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - L Divol
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - N Izumi
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - A Nikroo
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - K Baker
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - O Jones
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - O L Landen
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - W W Hsing
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - J D Moody
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - C A Thomas
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - B Lahmann
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J Williams
- General Atomics, San Diego, California 92121, USA
| | - N Alfonso
- General Atomics, San Diego, California 92121, USA
| | - M E Schoff
- General Atomics, San Diego, California 92121, USA
| |
Collapse
|
15
|
Jeanmonod R, Rammohan G, Grimaldi M, Minor M, Stankewicz H, Patterson R, Pester J, Baker K, Melanson S, Jeanmonod D. 299 Pediatric Airway Procedures Skill Retention with Standard Simulation, the Peyton Method, or Self-Directed Learning. Ann Emerg Med 2020. [DOI: 10.1016/j.annemergmed.2020.09.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Kilbride C, Scott D, Butcher T, Warland A, Ryan J, Norris M, Baker K, Anoyke N, Buxarrais GS, Athanasiou D, Nowicky A. Rehabilitation via home based gaming exercise for the upper-limb post stroke (RHOMBUS): results of an intervention feasibility trial. Physiotherapy 2020. [DOI: 10.1016/j.physio.2020.03.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Kwak P, Wesolowoski M, Baker K, Joyce C, Lowery E. Use of Cyclosporine Leads to Poorer Outcomes in Patients with Cystic Fibrosis Following Lung Transplant. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
18
|
O'Brien S, Garvey P, Baker K, Brennan M, Cormican M, Cuddihy J, De Lappe N, Ellard R, Fallon Ú, Irvine N, Murphy S, O'Brien D, O'Connor M, O'Hare C, O'Sullivan MB, Part AM, Rooney P, Ryan A, Waldron G, Ward M, McKeown PJ. Investigation of a foodborne outbreak of Shigella sonnei in Ireland and Northern Ireland, December 2016: the benefits of cross-border collaboration and commercial sales data. Public Health 2020; 182:19-25. [PMID: 32120067 DOI: 10.1016/j.puhe.2020.01.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Revised: 12/11/2019] [Accepted: 01/09/2020] [Indexed: 11/16/2022]
Abstract
OBJECTIVES To describe a cross-border foodborne outbreak of Shigella sonnei that occurred in Ireland and Northern Ireland (NI) in December 2016 whilst also highlighting the valuable roles of sales data and international collaboration in the investigation and control of this outbreak. STUDY DESIGN A cross-border outbreak control team was established to investigate the outbreak. METHODS Epidemiological, microbiological, and environmental investigations were undertaken. Traditional analytical epidemiological studies were not feasible in this investigation. The restaurant chain provided sales data, which allowed assessment of a possible increased risk of illness associated with exposure to a particular type of heated food product (product A). RESULTS Confirmed cases demonstrated sole trimethoprim resistance: an atypical antibiogram for Shigella isolates in Ireland. Early communication and the sharing of information within the outbreak control team facilitated the early detection of the international dimension of this outbreak. A joint international alert using the European Centre for Disease Control's confidential Epidemic Intelligence Information System for Food- and Waterborne Diseases and Zoonoses (EPIS-FWD) did not reveal further cases outside of the island of Ireland. The outbreak investigation identified that nine of thirteen primary case individuals had consumed product A from one of multiple branches of a restaurant chain located throughout the island of Ireland. Product A was made specifically for this chain in a food production facility in NI. S. sonnei was not detected in food samples from the food production facility. Strong statistical associations were observed between visiting a branch of this restaurant chain between 5 and 9 December 2016 and eating product A and developing shigellosis. CONCLUSIONS This outbreak investigation highlights the importance of international collaboration in the efficient identification of cross-border foodborne outbreaks and the value of using sales data as the analytical component of such studies.
Collapse
Affiliation(s)
- S O'Brien
- HSE-Health Protection Surveillance Centre, Dublin, Ireland; Department of Public Health HSE-NW, Sligo, Ireland.
| | - P Garvey
- HSE-Health Protection Surveillance Centre, Dublin, Ireland
| | - K Baker
- Food Standards Agency Northern Ireland, Belfast, Northern Ireland, Ireland
| | - M Brennan
- Food Safety Authority of Ireland, Dublin, Ireland
| | - M Cormican
- National Salmonella, Shigella and Listeria Reference Laboratory, Galway, Ireland
| | - J Cuddihy
- Department of Public Health HSE-SE, Kilkenny, Ireland
| | - N De Lappe
- National Salmonella, Shigella and Listeria Reference Laboratory, Galway, Ireland
| | - R Ellard
- Food Safety Authority of Ireland, Dublin, Ireland
| | - Ú Fallon
- Department of Public Health HSE-Midlands, Co Offaly, Ireland
| | - N Irvine
- Public Health Agency Northern Ireland, Belfast, Northern Ireland, UK
| | - S Murphy
- Environmental Health Department, Newry, Mourne & Down District Council, Northern Ireland, UK
| | - D O'Brien
- HSE Environmental Health Service Dublin Specialist Section, Dublin, Ireland
| | - M O'Connor
- Department of Public Health HSE-E, Dublin, Ireland
| | - C O'Hare
- Department of Public Health HSE-SE, Kilkenny, Ireland
| | | | - A M Part
- HSE Environmental Health Service Dublin Mid Leinster, Dublin, Ireland
| | - P Rooney
- Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK
| | - A Ryan
- Department of Public Health HSE-NW, Sligo, Ireland
| | - G Waldron
- Public Health Agency Northern Ireland, Belfast, Northern Ireland, UK
| | - M Ward
- Department of Public Health HSE-E, Dublin, Ireland
| | - P J McKeown
- HSE-Health Protection Surveillance Centre, Dublin, Ireland
| | | |
Collapse
|
19
|
Gomes F, Baker K, Woods J, Bruce J, Eaton M, Higham P, Cove-Smith L, Garbett A, Cree A, Ng C, Blackhall F, Bayman N. MA19.09 Assessing Clinical Frailty in Advanced Lung Cancer Patients - An Opportunity to Improve Patient Outcomes? J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.661] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Lindsay C, Rafee S, Nicola P, Wallace A, Burghel G, Schlecht H, Baker K, Baker E, Priest L, Rogan J, Moghadam S, Carter M, Newman W, Blackhall F. MA25.08 Characterisation of Tumor Aetiology Using Mutational Signatures from the Non-Small Cell Lung Cancer Genome. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Arden J, Quinn T, Wilson T, Hanna A, Baker K, Baschnagel A, Wilson G. Automated Assessment of Biomarker Expression in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients Shows Association between High CD44, c-MET, EGFR, and GLUT1 Expression with Decreased Disease-Free Survival and Overall Survival. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
22
|
Read M, Modasia B, Fletcher A, Thompson R, Baker K, Boelaert K, Turnell A, Smith V, Mehanna H, McCabe C. PO-124 PTTG and PBF functionally interact with P53 and predict overall survival in head and neck cancer. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
23
|
Fenemore J, Punnett G, Yorke J, Blackhall F, Baker K. Identification of support and information needs along the care pathway for patients with non-small cell lung cancer (NSCLC) receiving treatment with curative intent chemo-radiotherapy: emerging findings from the INSIGHT study. Lung Cancer 2018. [DOI: 10.1016/s0169-5002(18)30173-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
George S, Vanhoff K, Baker K, Lake L, Rolfe P, Seewald W, Emery D. Application of a coproantigen ELISA as an indicator of efficacy against multiple life stages of Fasciola hepatica infections in sheep. Vet Parasitol 2017; 246:60-69. [DOI: 10.1016/j.vetpar.2017.08.028] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2017] [Revised: 08/18/2017] [Accepted: 08/24/2017] [Indexed: 10/18/2022]
|
25
|
Gomes F, Woolley S, Califano R, Summers Y, Baker K, Burns K, Yorke J, Blackhall F. MA 10.07 Elderly Lung Cancer Patients on Immunotherapy: Preliminary Results from the ELDERS Study. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.538] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
26
|
Geiger C, Baker K, Redman M, Goulart B, Eaton K, Martins R, Baik C. P1.06-009 Barriers to Clinical Trial Participation in Lung Cancer Patients, a Single Institution Experience. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
Hashimoto T, Yoshida K, Goto T, Yako T, Muralidharan A, Baker K, Vitek J. Thalamic responses to somatosensory input are reduced in cerebellar ataxia. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Cook M, Lachance K, Nguyen M, Redman M, Baker K, Tseng Y, Nghiem P. 365 Outcomes among Merkel cell carcinoma patients with chronic immunosuppression. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Bayramian A, Aceves S, Anklam T, Baker K, Bliss E, Boley C, Bullington A, Caird J, Chen D, Deri R, Dunne M, Erlandson A, Flowers D, Henesian M, Latkowski J, Manes K, Molander W, Moses E, Piggott T, Powers S, Rana S, Rodriguez S, Sawicki R, Schaffers K, Seppala L, Spaeth M, Sutton S, Telford S. Compact, Efficient Laser Systems Required for Laser Inertial Fusion Energy. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-313] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. Bayramian
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - S. Aceves
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - T. Anklam
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - K. Baker
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - E. Bliss
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - C. Boley
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - A. Bullington
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - J. Caird
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - D. Chen
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - R. Deri
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - M. Dunne
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - A. Erlandson
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - D. Flowers
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - M. Henesian
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - J. Latkowski
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - K. Manes
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - W. Molander
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - E. Moses
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - T. Piggott
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - S. Powers
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - S. Rana
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - S. Rodriguez
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - R. Sawicki
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - K. Schaffers
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - L. Seppala
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - M. Spaeth
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - S. Sutton
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - S. Telford
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| |
Collapse
|
30
|
Fuller M, Stewart M, Baker K. Knowledge and Skill Retention of a Novel Lay-Provider Trauma Training
Curriculum in Rural Peru: A Longitudinal Study. Ann Glob Health 2017. [DOI: 10.1016/j.aogh.2017.03.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
31
|
Wolf J, Lourenco A, Alpers J, Rohatgi N, Constantini C, Hollingsworth A, Grobmyer S, Pederson H, Haythem A, Polen W, Northfelt D, Morris M, Baker K, Ghosh K, Kass F, Arterbery E, Yang R, Tran Q, Letsios E, Mulpuri R, Reese DE. Abstract P1-02-08: Provista-002: A prospective, multi-center study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 3, 4 and 5 imaging reports. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-02-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- J Wolf
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - A Lourenco
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - J Alpers
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - N Rohatgi
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - C Constantini
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - A Hollingsworth
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - S Grobmyer
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - H Pederson
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - A Haythem
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - W Polen
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - D Northfelt
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - M Morris
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - K Baker
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - K Ghosh
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - F Kass
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - E Arterbery
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - R Yang
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - Q Tran
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - E Letsios
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - R Mulpuri
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - DE Reese
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| |
Collapse
|
32
|
|
33
|
Rengan R, Baker K, Salazar L, Childs J, Higgins D, Redman M, Reichow J, Disis ML. Abstract P2-11-05: Overall survival in inflammatory breast cancer patients receiving Her-2 Neu directed tumor vaccine therapy: Matched comparison with SEER registry patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-11-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Patients with inflammatory breast cancer (IBC) have a poor prognosis, primarily due to distant dissemination. Additionally, IBC patients have an increased rate of HER2 overexpression when compared to patients with non-inflammatory breast cancer. The forms the rationale for HER2 directed tumor vaccine therapy in these patients. The purpose of this study was to examine overall survival in IBC patients receiving HER2 directed tumor vaccine therapy when compared with matched control patients from the SEER Registry.
Methods
Patients with diagnosis of Stage III or IV HER2 positive IBC having completed standard initial therapy and without evidence of disease received HER2 vaccinations after being enrolled on 5 prospective clinical trials. Overall survival data were pooled and analyzed. A control group of matched IBC patients were identified by querying the SEER database from 1997-2011. The control group was identified as any individual in the database with a code for IBC. A secondary analysis comparing survival in HER2 positive IBC vs HER2 negative IBC patients was performed by querying the SEER database from 2010 onwards, the time point when the HER2 status was coded in the database. Propensity score adjustment were made to the control group to account for any imbalances between groups in measured covariates such as stage, race, age, sex, and era of enrollment and the time interval from diagnosis to enrollment on vaccine trial (median ∼2 years).
Results
A total of 37 IBC patients received HER2 directed vaccine therapy and 676 patients were identified for the SEER control group; Stage at enrollment: stage IIIB: 30 patients in the vaccine group and 639 patients in the control group; stage IIIC: 1 patient in the vaccine group and 15 patients in the control group; stage IV 6 patients in the vaccine group and 22 in the control group. The median survival of the overall population was 112 months for the vaccine group and 47 months for the control group (p=0.04). After using propensity scores to adjust the control for imbalances in measured covariates, the median survival for the overall population was 112 months for the vaccine group and 37 months for the control group (p=0.03). There was no difference in survival between HER2 positive and HER2 negative IBC patients in the control group (p=0.6).
Conclusion
These results demonstrate promising overall survival in HER2 positive IBC patients receiving HER2 directed vaccine therapy after initial therapy. Propensity matching was performed to adjust for imbalances in measured covariates and resulted in a modest decrease in survival of the control group after adjustment, suggesting that the vaccine trial group had relatively unfavorable pre-treatment characteristics. Despite these unfavorable characteristics, patients receiving vaccine had a median survival of 112 months. These results must be further confirmed in a prospective randomized trial.
Citation Format: Rengan R, Baker K, Salazar L, Childs J, Higgins D, Redman M, Reichow J, Disis ML. Overall survival in inflammatory breast cancer patients receiving Her-2 Neu directed tumor vaccine therapy: Matched comparison with SEER registry patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-11-05.
Collapse
Affiliation(s)
- R Rengan
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - K Baker
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - L Salazar
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - J Childs
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - D Higgins
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - M Redman
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - J Reichow
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - ML Disis
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| |
Collapse
|
34
|
Abstract
Natural systems dominated by sediment transport are notoriously difficult to forecast. This is particularly true along the ocean coastline, a region that draws considerable human attention as economic investment and infrastructure are threatened by both persistent, long-term and acute, event driven processes (i.e., sea level rise and storm damage, respectively). Forecasting the coastline's evolution over intermediate time (daily) and space (tens of meters) scales is hindered by the complexity of sediment transport and hydrodynamics, and limited access to the detailed local forcing that drives fast scale processes. Modern remote sensing systems provide an efficient, economical means to collect data within these regions. A solar-powered digital camera installation is used to capture the coast's evolution, and machine learning algorithms are implemented to extract the shoreline and estimate the daily mean intertidal coastal profile. Methods in nonlinear time series forecasting and genetic programming applied to these data corroborate that coastal morphology at these scales is predominately driven by nonlinear internal dynamics, which partially mask external forcing signatures. Results indicate that these forecasting techniques achieve nontrivial predictive skill for spatiotemporal forecast of the upper coastline profile (as much as 43% of variance in data explained for one day predictions). This analysis provides evidence that societally relevant coastline forecasts can be achieved without knowing the forcing environment or the underlying dynamical equations that govern coastline evolution.
Collapse
Affiliation(s)
- D J Grimes
- Integrative Oceanography Division, Scripps Institution of Oceanography, University of California San Diego, La Jolla, California 92037, USA
| | - N Cortale
- Center for Marine Science, University of North Carolina Wilmington, Wilmington, North Carolina 28409, USA
| | - K Baker
- Geodynamics Group, LLC, Newport, North Carolina 28570, USA
| | - D E McNamara
- Department of Physics and Physical Oceanography, University of North Carolina Wilmington, Wilmington, North Carolina 28403, USA
| |
Collapse
|
35
|
Kiwanuka J, Ttendo S, Eromo E, Joseph S, Duan M, Haastrup A, Baker K, Firth P. Synchronous distance anesthesia education by Internet videoconference between Uganda and the United States. J Clin Anesth 2015; 27:499-503. [DOI: 10.1016/j.jclinane.2015.04.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2014] [Revised: 03/27/2015] [Accepted: 04/16/2015] [Indexed: 11/26/2022]
|
36
|
Pathak G, Ibrahim BA, McCarthy SA, Baker K, Kelly MP. Amphetamine sensitization in mice is sufficient to produce both manic- and depressive-related behaviors as well as changes in the functional connectivity of corticolimbic structures. Neuropharmacology 2015; 95:434-47. [PMID: 25959066 DOI: 10.1016/j.neuropharm.2015.04.026] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2014] [Revised: 04/21/2015] [Accepted: 04/24/2015] [Indexed: 10/23/2022]
Abstract
It has been suggested that amphetamine abuse and withdrawal mimics the diverse nature of bipolar disorder symptomatology in humans. Here, we determined if a single paradigm of amphetamine sensitization would be sufficient to produce both manic- and depressive-related behaviors in mice. CD-1 mice were subcutaneously dosed for 5 days with 1.8 mg/kg d-amphetamine or vehicle. On days 6-31 of withdrawal, amphetamine-sensitized (AS) mice were compared to vehicle-treated (VT) mice on a range of behavioral and biochemical endpoints. AS mice demonstrated reliable mania- and depression-related behaviors from day 7 to day 28 of withdrawal. Relative to VT mice, AS mice exhibited long-lasting mania-like hyperactivity following either an acute 30-min restraint stress or a low-dose 1 mg/kg d-amphetamine challenge, which was attenuated by the mood-stabilizers lithium and quetiapine. In absence of any challenge, AS mice showed anhedonia-like decreases in sucrose preference and depression-like impairments in the off-line consolidation of motor memory, as reflected by the lack of spontaneous improvement across days of training on the rotarod. AS mice also demonstrated a functional impairment in nest building, an ethologically-relevant activity of daily living. Western blot analyses revealed a significant increase in methylation of histone 3 at lysine 9 (H3K9), but not lysine 4 (H3K4), in hippocampus of AS mice relative to VT mice. In situ hybridization for the immediate-early gene activity-regulated cytoskeleton-associated protein (Arc) further revealed heightened activation of corticolimbic structures, decreased functional connectivity between frontal cortex and striatum, and increased functional connectivity between the amygdala and hippocampus of AS mice. The effects of amphetamine sensitization were blunted in C57BL/6J mice relative to CD-1 mice. These results show that a single amphetamine sensitization protocol is sufficient to produce behavioral, functional, and biochemical phenotypes in mice that are relevant to bipolar disorder.
Collapse
Affiliation(s)
- G Pathak
- University of South Carolina School of Medicine, Columbia, SC 29209, USA
| | - B A Ibrahim
- University of South Carolina School of Medicine, Columbia, SC 29209, USA
| | | | - K Baker
- Pfizer, Neuroscience, Groton, CT 06340, USA
| | - M P Kelly
- University of South Carolina School of Medicine, Columbia, SC 29209, USA.
| |
Collapse
|
37
|
Devos H, Baker K, Phillips K, Akinwuntan A. Improvement of driving skills in persons with relapsing-remitting multiple sclerosis. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
38
|
Woodard B, Baker K. New Cervical Cancer Screening Guidelines: Are We Doing Our Job? J Minim Invasive Gynecol 2015. [DOI: 10.1016/j.jmig.2014.12.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
39
|
Chaudhry A, Noor A, Degagne B, Baker K, Bok LA, Brady AF, Chitayat D, Chung BH, Cytrynbaum C, Dyment D, Filges I, Helm B, Hutchison HT, Jeng LJB, Laumonnier F, Marshall CR, Menzel M, Parkash S, Parker MJ, Raymond LF, Rideout AL, Roberts W, Rupps R, Schanze I, Schrander-Stumpel CTRM, Speevak MD, Stavropoulos DJ, Stevens SJC, Thomas ERA, Toutain A, Vergano S, Weksberg R, Scherer SW, Vincent JB, Carter MT. Phenotypic spectrum associated withPTCHD1deletions and truncating mutations includes intellectual disability and autism spectrum disorder. Clin Genet 2014; 88:224-33. [DOI: 10.1111/cge.12482] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2014] [Revised: 08/08/2014] [Accepted: 08/08/2014] [Indexed: 11/28/2022]
Affiliation(s)
- A. Chaudhry
- Department of Pediatrics; Division of Clinical and Metabolic Genetics; The Hospital for Sick Children; Toronto Ontario Canada
| | - A. Noor
- Department of Pathology and Laboratory Medicine; The Hospital for Sick Children; Toronto Ontario Canada
- Molecular Neuropsychiatry and Development Lab; Campbell Family Mental Health Research Institute, The Centre for Addiction and Mental Health; Toronto Ontario Canada
| | - B. Degagne
- Molecular Neuropsychiatry and Development Lab; Campbell Family Mental Health Research Institute, The Centre for Addiction and Mental Health; Toronto Ontario Canada
| | - K. Baker
- Department of Medical Genetics; Cambridge UK
- Institute for Medical Research Wellcome Trust; University of Cambridge; Cambridge UK
| | - L. A. Bok
- Department of Clinical Genetics, Unit of Cytogenetics; Maastricht University Medical Center; Maastricht The Netherlands
| | - A. F. Brady
- North West Thames Regional Genetics Service; Northwick Park Hospital; Harrow UK
| | - D. Chitayat
- Department of Pediatrics; Division of Clinical and Metabolic Genetics; The Hospital for Sick Children; Toronto Ontario Canada
- The Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital; University of Toronto; Toronto Ontario Canada
| | - B. H. Chung
- Department of Pediatrics and Adolescent Medicine, Department of Obstetrics and Gynaecology, Centre for Reproduction, Development and Growth, Centre for Genomic Sciences; The University of Hong Kong; Pok Fu Lam, Hong Kong
| | - C. Cytrynbaum
- Department of Pediatrics; Division of Clinical and Metabolic Genetics; The Hospital for Sick Children; Toronto Ontario Canada
- Genetics and Genome Biology; The Hospital for Sick Children; Toronto Ontario Canada
| | - D. Dyment
- Department of Genetics; Children's Hospital of Eastern Ontario; Ottawa Ontario Canada
| | - I. Filges
- Division of Medical Genetics, Department of Biomedicine; University Hospital Basel; Basel Switzerland
| | - B. Helm
- Division of Medical Genetics and Metabolism; Children's Hospital of The King's Daughters/Eastern Virginia Medical School; Norfolk VA USA
| | - H. T. Hutchison
- Departments of Neurology and Pediatrics; UCSF Fresno Medical Education Program; San Francisco CA USA
| | - L. J. B. Jeng
- Department of Laboratory Medicine; University of California; San Francisco CA USA
| | - F. Laumonnier
- UMR_INSERM U930 Faculté de Médecine; Université François Rabelais; Tours France
| | - C. R. Marshall
- The Centre for Applied Genomics; The Hospital for Sick Children; Toronto Ontario Canada
| | | | - S. Parkash
- Maritime Medical Genetics Service; IWK Health Centre; Halifax Nova Scotia Canada
- Dalhousie University Halifax; Nova Scotia Canada
| | - M. J. Parker
- Sheffield Clinical Genetics Service; Sheffield Children's Hospital; Western Bank Sheffield UK
| | - L. F. Raymond
- Department of Medical Genetics; Cambridge UK
- Institute for Medical Research Wellcome Trust; University of Cambridge; Cambridge UK
| | - A. L. Rideout
- Maritime Medical Genetics Service; IWK Health Centre; Halifax Nova Scotia Canada
| | - W. Roberts
- Autism Research Unit; The Hospital for Sick Children; Toronto Ontario Canada
| | - R. Rupps
- Department of Medical Genetics, Children's and Women's Health Centre; University of British Columbia; Vancouver BC Canada
| | - I. Schanze
- Institute of Human Genetics; University Hospital Magedeburg; Magedeburg Germany
| | - C. T. R. M. Schrander-Stumpel
- Department of Clinical Genetics and School for Oncology & Developmental Biology (GROW); Maastricht UMC+; Maastricht The Netherlands
| | - M. D. Speevak
- Credit Valley Site, Trillium Health Partners, Department of Laboratory Medicine and Pathobiology; University of Toronto; Toronto Onatario Canada
| | - D. J. Stavropoulos
- Department of Pathology and Laboratory Medicine; The Hospital for Sick Children; Toronto Ontario Canada
- The Centre for Applied Genomics; The Hospital for Sick Children; Toronto Ontario Canada
| | - S. J. C. Stevens
- Department of Clinical Genetics and School for Oncology & Developmental Biology (GROW); Maastricht UMC+; Maastricht The Netherlands
| | - E. R. A. Thomas
- Clinical Genetics Department; Guy's and St Thomas' NHS Foundation Trust; London UK
| | - A. Toutain
- UMR_INSERM U930 Faculté de Médecine; Université François Rabelais; Tours France
- Service de Génétique; Centre Hospitalo-Universitaire; Tours France
| | - S. Vergano
- Division of Medical Genetics and Metabolism; Children's Hospital of The King's Daughters/Eastern Virginia Medical School; Norfolk VA USA
| | - R. Weksberg
- Department of Pediatrics; Division of Clinical and Metabolic Genetics; The Hospital for Sick Children; Toronto Ontario Canada
- Institute of Medical Science; Toronto Ontario Canada
- McLaughlin Centre and Department of Molecular Genetics; Toronto Ontario Canada
| | - S. W. Scherer
- The Centre for Applied Genomics; The Hospital for Sick Children; Toronto Ontario Canada
- Institute of Medical Science; Toronto Ontario Canada
- McLaughlin Centre and Department of Molecular Genetics; Toronto Ontario Canada
| | - J. B. Vincent
- Molecular Neuropsychiatry and Development Lab; Campbell Family Mental Health Research Institute, The Centre for Addiction and Mental Health; Toronto Ontario Canada
- Institute of Medical Science; Toronto Ontario Canada
- Department of Psychiatry; University of Toronto; Toronto Ontario Canada
| | - M. T. Carter
- Department of Pediatrics; Division of Clinical and Metabolic Genetics; The Hospital for Sick Children; Toronto Ontario Canada
- Autism Research Unit; The Hospital for Sick Children; Toronto Ontario Canada
| | | |
Collapse
|
40
|
Bionta MR, Hartmann N, Weaver M, French D, Nicholson DJ, Cryan JP, Glownia JM, Baker K, Bostedt C, Chollet M, Ding Y, Fritz DM, Fry AR, Kane DJ, Krzywinski J, Lemke HT, Messerschmidt M, Schorb S, Zhu D, White WE, Coffee RN. Spectral encoding method for measuring the relative arrival time between x-ray/optical pulses. Rev Sci Instrum 2014; 85:083116. [PMID: 25173255 DOI: 10.1063/1.4893657] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
The advent of few femtosecond x-ray light sources brings promise of x-ray/optical pump-probe experiments that can measure chemical and structural changes in the 10-100 fs time regime. Widely distributed timing systems used at x-ray Free-Electron Laser facilities are typically limited to above 50 fs fwhm jitter in active x-ray/optical synchronization. The approach of single-shot timing measurements is used to sort results in the event processing stage. This has seen wide use to accommodate the insufficient precision of active stabilization schemes. In this article, we review the current technique for "measure-and-sort" at the Linac Coherent Light Source at the SLAC National Accelerator Laboratory. The relative arrival time between an x-ray pulse and an optical pulse is measured near the experimental interaction region as a spectrally encoded cross-correlation signal. The cross-correlation provides a time-stamp for filter-and-sort algorithms used for real-time sorting. Sub-10 fs rms resolution is common in this technique, placing timing precision at the same scale as the duration of the shortest achievable x-ray pulses.
Collapse
Affiliation(s)
- M R Bionta
- Université de Toulouse, UPS, Laboratoire Collisions Agrégats Réactivité, IRSAMC, F-31062 Toulouse, France
| | - N Hartmann
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - M Weaver
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - D French
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - D J Nicholson
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - J P Cryan
- Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, California 94720, USA
| | - J M Glownia
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - K Baker
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551, USA
| | - C Bostedt
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - M Chollet
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - Y Ding
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - D M Fritz
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - A R Fry
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - D J Kane
- Mesa Photonics, LLC., 1550 Pacheco St., Santa Fe, New Mexico 87505, USA
| | - J Krzywinski
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - H T Lemke
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - M Messerschmidt
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - S Schorb
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - D Zhu
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - W E White
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - R N Coffee
- The Linac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| |
Collapse
|
41
|
Rankine L, Grantham K, Goddu S, Cessac R, Baker K, Klein E, Santanam L. SU-E-J-244: Validation of a 6D-Robotic-Couch and Image Guidance Radiation Therapy (IGRT) System for Localization in World's First Single-Room Proton Therapy System. Med Phys 2014. [DOI: 10.1118/1.4888297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
42
|
Caremel R, Tu L, Baker K, Lotouchin O, Corcos J. Étude randomisée, prospective, multicentrique comparant un traitement médical à un traitement chirurgical dans l’incontinence urinaire mixte de la femme. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
43
|
McGill J, Baker K, Starks C, Barazani Y, Sabanegh E. The effects of pyospermia and ureaplasma urealyticum culture positivity on semen quality in subfertile men. Fertil Steril 2013. [DOI: 10.1016/j.fertnstert.2013.07.1302] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
44
|
Baker K, Barazani Y, Sabanegh E. Mind the gap: subjects below world health organization 4th ed (who 4) but above who 5th ed (who 5) minimum reference values have substantial odds of abnormal semen results on subsequent testing. Fertil Steril 2013. [DOI: 10.1016/j.fertnstert.2013.07.544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
45
|
Baker K, Foti M, Jastrzab L, Stringer E, Mackey S, Younger J. Immediate and lasting improvements in depression following rapid opioid detoxification. The Journal of Pain 2013. [DOI: 10.1016/j.jpain.2013.01.650] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
46
|
Foti M, Baker K, Jastrzab L, Stringer E, Mackey S, Younger J. Improvements in cognition following opioid detoxification program. The Journal of Pain 2013. [DOI: 10.1016/j.jpain.2013.01.641] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Goka E, Miller P, Baker K, Stark G, Lippman ME. Abstract P1-04-06: Insertional mutagenesis identifies HACE1 as a HER2/Neu Cooperating Breast Cancer Tumor Suppressor Gene. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-04-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The development of human breast cancer is a multi-step process leading from normal epithelium to fully transformed breast cancer. Early genetic changes result in hyperplasias which evolves into ductal carcinoma in situ (DCIS) and culminates as invasive ductal carcinoma. The transition from DCIS to invasive disease has been implicated as the key transition in breast cancer progression. Specific genomic, transcriptomic, and proteomic alterations responsible for this transition process have yet to been elucidated.
HER2/Neu, a member of the EGFR family of receptor tyrosine kinases, is associated with poor clinical outcome. HER2/Neu overexpression/amplification is commonly seen (50–60%) in non-invasive lesions but is significantly less common (20–30%) in invasive and metastatic breast carcinoma. This indicates that HER2/Neu gives normal epithelium a proliferative advantage but additional genetic alterations are required for full malignant transformation. This idea is supported by the fact that transgenic mice that overexpress HER2/Neu develop spontaneous mammary tumors but only after a prolonged latency period.
Recent forward genetic approaches use insertional mutagenesis to randomly integrate a strong promoter into the genome, activating downstream gene transcription that can lead to either gain or loss-of-function mutations based on the integration site. We used this insertional mutagenesis approach to induce anchorage-independent growth of isolated murine HER2/Neu over-expressing mammary epithelial cells. We identified HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 (HACE1) as a putative breast tumor suppressor protein whose loss leads to the formation of anchorage-independent colonies.
Loss of HACE1 expression is commonly seen in breast cancer patients [as well as other tumor types] supporting the role of HACE1 as a breast tumor suppressor gene. Knockdown of HACE1 in human mammary epithelial cells (HMECs) results in the acquisition of anchorage-independent growth. Moreover, knockdown of HACE1 in established breast cancer cell lines that express moderate levels of HACE1 results in enhanced cloniginicity.
Therefore, we propose that the loss of HACE1 can potentially be used as a predictive marker for breast cancer progression. Additional studies investigating the mechanism of HACE1 action may also identify therapeutic targets that counteract HACE1 loss.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-04-06.
Collapse
Affiliation(s)
- E Goka
- University of Miami Miller School of Medicine, Miami, FL; Cleveland Clinic, Cleveland, OH; University of Miami, FL
| | - P Miller
- University of Miami Miller School of Medicine, Miami, FL; Cleveland Clinic, Cleveland, OH; University of Miami, FL
| | - K Baker
- University of Miami Miller School of Medicine, Miami, FL; Cleveland Clinic, Cleveland, OH; University of Miami, FL
| | - G Stark
- University of Miami Miller School of Medicine, Miami, FL; Cleveland Clinic, Cleveland, OH; University of Miami, FL
| | - ME Lippman
- University of Miami Miller School of Medicine, Miami, FL; Cleveland Clinic, Cleveland, OH; University of Miami, FL
| |
Collapse
|
48
|
Romero-Suarez S, Mo C, Touchberry C, Lara N, Baker K, Craig R, Brotto L, Andresen J, Wacker M, Kaja S, Abreu E, Dillmann W, Mestril R, Brotto M, Nosek T. Hyperthermia: from diagnostic and treatments to new discoveries. Recent Pat Biotechnol 2012; 6:172-183. [PMID: 23092438 PMCID: PMC8865757 DOI: 10.2174/1872208311206030172] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2012] [Revised: 07/30/2012] [Accepted: 08/04/2012] [Indexed: 06/01/2023]
Abstract
Hyperthermia is an important approach for the treatment of several diseases. Hyperthermia is also thought to induce hypertrophy of skeletal muscles in vitro and in vivo, and has been used as a therapeutic tool for millennia. In the first part of our work, we revise several relevant patents related to the utilization of hyperthermia for the treatment and diagnostic of human diseases. In the second part, we present exciting new data on the effects of forced and natural overexpression of HSP72, using murine in vitro (muscle cells) and ex vivo (primary skeletal muscles) models. These studies help to demonstrate that hyperthermia effects are orchestrated by tight coupling between gene expression, protein function, and intracellular Ca2+ signaling pathways with a key role for calcium-induced calcium release. We hope that the review of current patents along with previous unknown information on molecular signaling pathways that underlie the hypertrophy response to hyperthermia in skeletal muscles may trigger the curiosity of scientists worldwide to explore new inventions that fully utilize hyperthermia for the treatment of muscle diseases.
Collapse
Affiliation(s)
- Sandra Romero-Suarez
- University of Missouri-Kansas City, Muscle Biology Research Group-MUBIG, School of Nursing
| | - Chenglin Mo
- University of Missouri-Kansas City, Muscle Biology Research Group-MUBIG, School of Nursing
| | | | - Nuria Lara
- Department of Oral Biology, School of Dentistry
| | - Kendra Baker
- University of Missouri-Kansas City, Muscle Biology Research Group-MUBIG, School of Nursing
| | - Robin Craig
- University of Missouri-Kansas City, Muscle Biology Research Group-MUBIG, School of Nursing
| | - Leticia Brotto
- University of Missouri-Kansas City, Muscle Biology Research Group-MUBIG, School of Nursing
| | - Jon Andresen
- University of Missouri-Kansas City, Muscle Biology Research Group-MUBIG, School of Nursing
- School of Medicine
| | - Michael Wacker
- University of Missouri-Kansas City, Muscle Biology Research Group-MUBIG, School of Nursing
- School of Medicine
| | - Simon Kaja
- Vision Research Center and Department of Ophthalmology, School of Medicine
| | - Eduardo Abreu
- University of Missouri-Kansas City, Muscle Biology Research Group-MUBIG, School of Nursing
| | | | - Ruben Mestril
- Loyola University Chicago, Department of Cell and Molecular Physiology
| | - Marco Brotto
- University of Missouri-Kansas City, Muscle Biology Research Group-MUBIG, School of Nursing
- School of Medicine
| | - Thomas Nosek
- Case Western Reserve University, School of Medicine
| |
Collapse
|
49
|
Basak S, Baker K, Babbur V. O089 B-LYNCH SUTURE IN MANAGEMENT OF POSTPARTUM HAEMORRHAGE - A FIVE-YEAR DISTRICT GENERAL HOSPITAL EXPERIENCE. Int J Gynaecol Obstet 2012. [DOI: 10.1016/s0020-7292(12)60519-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
50
|
Stout J, Queller S, Baker K, Borowsky B. J05 Development and characterisation of the cognitive assessment battery (CAB-HD) for Huntington's disease clinical trials. J Neurol Neurosurg Psychiatry 2012. [DOI: 10.1136/jnnp-2012-303524.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|